DiePharmazie 5/2004

All the research papers in this issue were presented during the 4th Conference on Retrometabolism Based Drug Design and Targeting, May 11-14, 2003, Palm Coast, Florida, USA

The Conference was sponsored by the University of Florida Center of Drug Discovery; The Nagai Foundation, Tokyo; IVAX Corporation; Janssen Pharmaceutical N.V.; Senju Pharmaceutical Co., Ltd.; Abbott Laboratories; Banyu Pharmaceutical Co., Ltd.; Hisamitsu Pharmaceutical Co., Ltd.; Otsuka Pharmaceutical Co., Ltd.; Santen Pharmaceutical Co., Ltd.; Terumo Corporation.



Brugos, B.; Hochhaus, G.: Metabolism of dynorphin A(1-13)


Original articles

Kuszmann, J.; Megyes, G.; Boros, S.: Synthesis of a polysulfated heparin degradation product

Csanádi, Ŕ.; Horváth, Gy.; Szekeres, T.; Haskó, T.; Ila, L.; Ivanics, J.; Patthy, M.; Salát, J.; Seres, G.; Pallagi, I.; Tóth, G.; Szederkényi, F.; Kónya, A.; Tegdes, A.; Bodor, N.; Zubovics, Z.: Etiprednol dicloacetate, a new soft glucocorticoid drug candidate. Development of chemistry

Loftsson, T.; Thorsteinsson, T.; Másson, M.: Marine lipids as building blocks for soft quaternary ammonium compounds and their antibacterial activity

Andrási, F.; Berzsenyi, P.; Farkas, L.; Kőrösi, J.; Hámori, T.; Botka, P.; Ling, I.; Láng, T.: Omeprazole and talampanel as two examples of retrometabolic drug design

Sahasranaman, S.; Issar, M.; Tóth, G.; Horváth, Gy.; Hochhaus, G.: Characterization of degradation products of mometasone furoate

Masubuchi, N.: Pharmacokinetics of DE-310, a novel macromolecular carrier system for the camptothecin analog DX-8951f, in tumor-bearing mice

Somogyi, G.; Buchwald, P.; Bodor, N.: Metabolic properties of phosphonate esters

Patthy, M.; Seres, G.; Csanádi, Ŕ.; Szekeres, T.; Zubovics, Z.; Bodor, N.: HPLC separation of related impurities in etiprednol dicloacetate, a novel soft corticosteroid

Brewster, M. E.; Verreck, G.; Chun, I.; Rosenblatt, J.; Mensch, J.; van Dijck, A.; Noppe, M.; Ariën, A.; Bruining, M.; Peeters, J.: The use of polymer-based electrospun nanofibers containing amorphous drug dispersions for the delivery of poorly water-soluble pharmaceuticals

Takayama, K.; Obata, Y.; Morishita, M.; Nagai, T.: Multivariate spline interpolation as a novel method to optimize pharmaceutical formulations

Buchwald, P.; Bodor, N.: Soft glucocorticoid design: structural elements and physicochemical parameters determining receptor-binding affinity

Kawakami, S.; Hattori, Y.; Lu, Y.; Higuchi, Y.; Yamashita, F.; Hashida, M.: Effect of cationic charge on receptor-mediated transfection using mannosylated cationic liposome/plasmid DNA complexes following the intravenous administration in mice

Szelenyi, I.; Hermann, R.; Petzold, U.; Pahl, A.; Hochhaus, G.: Possibilities in improvement of glucocorticoid treatments in asthma with special reference to loteprednol etabonate

Kurucz, I.; Németh, K.; Mészaros, S.; Török, K.; Nagy, Z.; Zubovics, Z.; Horváth, K.; Bodor, N.: Anti-inflammatory effect and soft properties of etiprednol dicloacetate (BNP-166), a new, anti-asthmatic steroid